Abstract
Aim/Introduction: Patients with neuroendocrine tumor liver metastases can beneft from additional holmium-166 (166Ho)-radioembolization after peptide receptor radionuclide therapy (PRRT). However, following radioembolization, hepatotoxicity is feared and has a large variation in its severity. The aim of this study is to assess the hepatotoxicity and the corresponding dose to the healthy
... read more